Abstract
Aptamers (Aps) are short single-strand nucleic acids exhibiting unique 3D structure which facilitate their targeting potential against various cancer molecular markers (CMMs). Such features of Aps not only make them as suitable homing agents in targeted drug delivery systems (DDSs) but also candidate them as macromolecules that inhibit the interaction of the target ligand with other proteins. On the other hand, the conjugation of Aps with another therapeutic molecule such as antisense oligonucleotides (ASOs), siRNAs/miRNAs, Aps, toxins, chemotherapeutic agents, DNAzymes/Ribozymes provides hopeful strategy to eradicate the malignancies and overcome the off-target unwanted side effects. Such prominent features of Aps make them a promising treatment modality to overcome the tumor complexity and heterogeneity, which can be consequently applied for personalized therapy of cancer by using bispecific Ap-based therapeutics.
| Original language | English |
|---|---|
| Pages (from-to) | 67-70 |
| Number of pages | 4 |
| Journal | BioImpacts |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2019 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 The Author(s). This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
ASJC Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology
- Pharmaceutical Science
Keywords
- Aptamedicine
- Aptamer
- Cancer therapy
- Drug delivery systems
- Nanomedicine
- Personalized medicine
Fingerprint
Dive into the research topics of 'Aptamedicine: A new treatment modality in personalized cancer therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS